ClinicalTrials.gg
CompletedNCT02276612Updated Nov 19, 2018Results posted

Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected Adolescents

A Phase 2/3 interventional study of E/C/F/TAF in HIV, sponsored by Gilead Sciences. Completed at 7 sites in 2 countries. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2018-11-19.

Sponsored by Gilead Sciences · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
12 Years to 17 Years
Sex
All
01

Study summary

The primary objective of this study is to evaluate the safety and tolerability of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) in HIV-infected virologically suppressed adolescents 12 to \< 18 years of age.

02

Conditions studied

  • HIV
03

In context

Lead sponsor

Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.

Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Currently on a stable antiretroviral regimen for ≥ 6 consecutive months
  • Weight ≥ 35 kg (77 lbs.)
  • Plasma -1 RNA levels \< 50 copies/mL for ≥ 6 months
  • > 100 cells/μL
  • No resistance to elvitegravir (EVG), emtricitabine (FTC), lamivudine (3TC) or tenofovir (TFV)
  • Hepatic transaminases ( and ALT) ≤ 5 x (ULN)
  • No evidence of current virus (HBV) infection
  • No evidence of current virus (HCV) infection

Note: participants from Gilead Study GS-US-162-0112 were allowed to roll over into this Study GS-US-292-1515 even if they were 18 years or older at the time of screening.

Key Exclusion Criteria:

  • A new AIDS-defining condition diagnosed within the 30 days prior to Screening
  • Evidence of active pulmonary or extra-pulmonary tuberculosis disease within 3 months of screening
  • Pregnant or lactating subjects

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    E/C/F/TAF

    Treatment-experienced participants will receive open-label E/C/F/TAF for up to 48 weeks. After completion of 48 weeks of treatment, all eligible participants will be given the option to participate in an open-label extension phase to receive E/C/F/TAF until a) the participant turns 18 years old and E/C/F/TAF is commercially available for use in adults in the country the participant is enrolled, or b) E/C/F/TAF becomes commercially available for use in the participant's current age group in the country the participant is enrolled, or c) E/C/F/TAF becomes accessible to participants through an access program, or d) Gilead Sciences elects to terminate development of E/C/F/TAF in the applicable country.

    Drug: E/C/F/TAF

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment-Emergent Serious Adverse Events

    The percentage of participants experiencing any treatment-emergent serious adverse event was summarized.

    Time frame: Up to Week 48

  2. Incidence of Treatment-Emergent Adverse Events

    The percentage of participants experiencing any treatment-emergent adverse event was summarized.

    Time frame: Up to Week 48

Secondary outcomes

  1. Percentage of Participants With Plasma HIV-1 RNA Level < 50 Copies/mL at Week 24 (FDA-defined Snapshot Analysis)

    The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 24 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

    Time frame: Week 24

  2. Percentage of Participants With Plasma HIV-1 RNA Level < 50 Copies/mL at Week 48 (FDA-defined Snapshot Analysis)

    The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

    Time frame: Week 48

  3. Change From Baseline in CD4 Cell Count at Week 24

    Time frame: Baseline; Week 24

  4. Change From Baseline in CD4 Cell Count at Week 48

    Time frame: Baseline; Week 48

  5. Change From Baseline in CD4 Percentage at Week 24

    Time frame: Baseline; Week 24

  6. Change From Baseline in CD4 Percentage at Week 48

    Time frame: Baseline; Week 48

07

Results

Posted Feb 22, 2018

Participant flow

Participants were enrolled at study sites in South Africa and the United States. The first participant was screened on 03 December 2014. The last study visit occurred on 23 October 2017.

Participant flow — Overall Study
MilestoneE/C/F/TAF (12 - 17 Years of Age)E/C/F/TAF (≥ 18 Years of Age)
Started5010
Completed4610
Not completed40
Withdrew: Death10
Withdrew: Pregnancy10
Withdrew: Withdrew consent10
Withdrew: Lost to follow-up10

Outcome measures

PrimaryIncidence of Treatment-Emergent Serious Adverse Events

The percentage of participants experiencing any treatment-emergent serious adverse event was summarized.

Time frame:
Up to Week 48
Reported as:
Number · percentage of participants
Incidence of Treatment-Emergent Serious Adverse Events
percentage of participantsE/C/F/TAF (12 - 17 Years of Age)E/C/F/TAF (≥ 18 Years of Age)
Incidence of Treatment-Emergent Serious Adverse Events4.00
PrimaryIncidence of Treatment-Emergent Adverse Events

The percentage of participants experiencing any treatment-emergent adverse event was summarized.

Time frame:
Up to Week 48
Reported as:
Number · percentage of participants
Incidence of Treatment-Emergent Adverse Events
percentage of participantsE/C/F/TAF (12 - 17 Years of Age)E/C/F/TAF (≥ 18 Years of Age)
Incidence of Treatment-Emergent Adverse Events92.0100.0
SecondaryPercentage of Participants With Plasma HIV-1 RNA Level < 50 Copies/mL at Week 24 (FDA-defined Snapshot Analysis)

The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 24 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With Plasma HIV-1 RNA Level < 50 Copies/mL at Week 24 (FDA-defined Snapshot Analysis)
percentage of participantsE/C/F/TAF (12 - 17 Years of Age)E/C/F/TAF (≥ 18 Years of Age)
Percentage of Participants With Plasma HIV-1 RNA Level < 50 Copies/mL at Week 24 (FDA-defined Snapshot Analysis)96.0 (86.3 to 99.5)100.0 (69.2 to 100.0)
SecondaryPercentage of Participants With Plasma HIV-1 RNA Level < 50 Copies/mL at Week 48 (FDA-defined Snapshot Analysis)

The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With Plasma HIV-1 RNA Level < 50 Copies/mL at Week 48 (FDA-defined Snapshot Analysis)
percentage of participantsE/C/F/TAF (12 - 17 Years of Age)E/C/F/TAF (≥ 18 Years of Age)
Percentage of Participants With Plasma HIV-1 RNA Level < 50 Copies/mL at Week 48 (FDA-defined Snapshot Analysis)90.0 (78.2 to 96.7)100.0 (69.2 to 100.0)
SecondaryChange From Baseline in CD4 Cell Count at Week 24
Time frame:
Baseline; Week 24
Reported as:
Mean · cells/µL
Change From Baseline in CD4 Cell Count at Week 24
cells/µLE/C/F/TAF (12 - 17 Years of Age)E/C/F/TAF (≥ 18 Years of Age)
Change From Baseline in CD4 Cell Count at Week 24-72 ± 189.8-85 ± 245.9
SecondaryChange From Baseline in CD4 Cell Count at Week 48
Time frame:
Baseline; Week 48
Reported as:
Mean · cells/µL
Change From Baseline in CD4 Cell Count at Week 48
cells/µLE/C/F/TAF (12 - 17 Years of Age)E/C/F/TAF (≥ 18 Years of Age)
Change From Baseline in CD4 Cell Count at Week 48-43 ± 201.1-41 ± 143.0
SecondaryChange From Baseline in CD4 Percentage at Week 24
Time frame:
Baseline; Week 24
Reported as:
Mean · percentage
Change From Baseline in CD4 Percentage at Week 24
percentageE/C/F/TAF (12 - 17 Years of Age)E/C/F/TAF (≥ 18 Years of Age)
Change From Baseline in CD4 Percentage at Week 24-0.6 ± 5.46-0.6 ± 5.46
SecondaryChange From Baseline in CD4 Percentage at Week 48
Time frame:
Baseline; Week 48
Reported as:
Mean · percentage
Change From Baseline in CD4 Percentage at Week 48
percentageE/C/F/TAF (12 - 17 Years of Age)E/C/F/TAF (≥ 18 Years of Age)
Change From Baseline in CD4 Percentage at Week 48-0.1 ± 3.95-1.1 ± 7.29

Adverse events

Collected over Up to 128 weeks plus 30 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
E/C/F/TAF (12 - 17 Years of Age)1/50 (2%)3/50 (6%)42/50 (84%)
E/C/F/TAF (≥ 18 Years of Age)0/10 (0%)0/10 (0%)10/10 (100%)
Most frequent serious events
Most frequent serious events
EventE/C/F/TAF (12 - 17 Years of Age)E/C/F/TAF (≥ 18 Years of Age)
VomitingGastrointestinal disorders1/500/10
ElectrocutionGeneral disorders1/500/10
Abortion spontaneousPregnancy, puerperium and perinatal conditions1/500/10
Most frequent other events
Showing 10 of 48
Most frequent other events
EventE/C/F/TAF (12 - 17 Years of Age)E/C/F/TAF (≥ 18 Years of Age)
Upper respiratory tract infectionInfections and infestations11/506/10
CoughRespiratory, thoracic and mediastinal disorders12/505/10
Nasal obstructionRespiratory, thoracic and mediastinal disorders3/503/10
DiarrhoeaGastrointestinal disorders7/502/10
Oral herpesInfections and infestations1/502/10
HeadacheNervous system disorders6/502/10
VomitingGastrointestinal disorders8/501/10
Viral upper respiratory tract infectionInfections and infestations7/500/10
Vitamin D decreasedInvestigations7/500/10
AcneSkin and subcutaneous tissue disorders6/500/10

Baseline characteristics

Safety Analysis Set: participants who were enrolled in the study and received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)E/C/F/TAF (12 - 17 Years of Age)E/C/F/TAF (≥ 18 Years of Age)Total
Mean15 ± 1.619 ± 1.216 ± 2.2
Sex: Female, Male
Sex: Female, Male(Participants)E/C/F/TAF (12 - 17 Years of Age)E/C/F/TAF (≥ 18 Years of Age)Total
Female32335
Male18725
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)E/C/F/TAF (12 - 17 Years of Age)E/C/F/TAF (≥ 18 Years of Age)Total
Hispanic or Latino101
Not Hispanic or Latino491059
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)E/C/F/TAF (12 - 17 Years of Age)E/C/F/TAF (≥ 18 Years of Age)Total
Black49958
White101
Other011
Region of Enrollment
Region of Enrollment(Participants)E/C/F/TAF (12 - 17 Years of Age)E/C/F/TAF (≥ 18 Years of Age)Total
United States808
South Africa421052
HIV-1 RNA Category
HIV-1 RNA Category(Participants)E/C/F/TAF (12 - 17 Years of Age)E/C/F/TAF (≥ 18 Years of Age)Total
< 50 copies/mL49958
≥ 50 copies/mL112
CD4 Cell Count
CD4 Cell Count(cells/µL)E/C/F/TAF (12 - 17 Years of Age)E/C/F/TAF (≥ 18 Years of Age)Total
Mean753 ± 222.5776 ± 179.9757 ± 214.8
CD4 Percentage
CD4 Percentage(percentage)E/C/F/TAF (12 - 17 Years of Age)E/C/F/TAF (≥ 18 Years of Age)Total
Mean34.3 ± 6.7235.9 ± 6.5334.6 ± 6.66
08

Study locations

7 sites
  • Tampa, Florida, United States
  • Detroit, Michigan, United States
  • New York, New York, United States
  • Memphis, Tennessee, United States
  • Cape Town, South Africa
  • Johannesburg, South Africa
  • Soweto, South Africa
09

References and documents

Individual participant data

Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at http://www.gilead.com/research/disclosure-and-transparency.

Supporting information: Study protocol, Statistical analysis plan

Time frame: 18 months after study completion

Access criteria: A secured external environment with username, password, and RSA code.

Data sharing details ↗ · www.gilead.com

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2014 to primary completion in Nov 2016, 23 months.

Results were first posted in Feb 2018, 1 year 3 months after primary completion. A results delay was requested in Oct 2017.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 24, 2014
First posted
Oct 28, 2014
StartActual
Dec 3, 2014
Primary completionActual
Nov 10, 2016
CompletionActual
Oct 23, 2017
Results delay requested
Oct 19, 2017
Results first posted
Feb 22, 2018
Last update
Nov 19, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 19, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02276612
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Oct 28, 2014
Start date
Dec 3, 2014
Primary completion
Nov 10, 2016
Completion
Oct 23, 2017
Results posted
Feb 22, 2018
Last update
Nov 19, 2018

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Elvitegravir · Cobicistat · Emtricitabine · Tenofovir alafenamide

Start the discussion